Adipose-derived autologous stem cell therapy - U.S. Stem Cell

Drug Profile

Adipose-derived autologous stem cell therapy - U.S. Stem Cell

Alternative Names: AdipoCell (Bioheart); Bioheart Acute Cell Therapy; Implanted autologous adipose-derived stem cells - U.S. Stem Cell; LipiCell

Latest Information Update: 29 Mar 2017

Price : $50

At a glance

  • Originator Bioheart
  • Developer Magnum Cell Therapies; Revita Life Sciences; U.S. Stem Cell
  • Class Anti-ischaemics; Cardiovascular therapies; Erectile dysfunction therapies; Eye disorder therapies; Heart failure therapies; Stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Intervertebral disc degeneration
  • Phase I/II Heart failure
  • Clinical Phase Unknown Chronic obstructive pulmonary disease; Coronary disorders; Erectile dysfunction; Myocardial ischaemia; Peripheral ischaemia
  • No development reported Myocardial infarction

Most Recent Events

  • 15 Mar 2017 Bioheart withdrew prior to enrolment a clinical study for Chronic obstructive pulmonary disease in USA (NCT02041000)
  • 01 Jan 2017 Bioheart completes a clinical trial in Intervertebral disc degeneration in USA (NCT02097862)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Myocardial-infarction in USA (Intracardiac)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top